Feiba NF and Thrombo/hemorrhage
Result of checking the interaction of drug Feiba NF and disease Thrombo/hemorrhage for safety when used together.
When checking interaction based on authoritative sources Drugs.com, Rxlist.com, Webmd.com, Medscape.com there are contraindications or side effects that may cause harm or increase the negative effect from drug use in presence of concomitant diseases.
Consumer:The use of anti- inhibitor coagulant complex is contraindicated in patients with significant signs of fibrinolysis, disseminated intravascular coagulation (DIC), and acute thrombosis or embolism including myocardial infarction. Anti- inhibitor coagulant complex contains Factor VIII inhibitor bypassing activity and prothrombin complex factors and may cause or exacerbate fibrinolysis or coagulation. If DIC or fibrinolysis occurs during treatment, the infusion should be stopped promptly and appropriate therapeutic measures initiated. Thromboembolic events may also occur during treatment, particularly following the administration of large doses and/or in patients with thrombotic risk factors. Caution is advised when administering anti- inhibitor coagulant complex to patients with an active or past history of thromboembolic disorders.
- "Product Information. Autoplex T (anti-inhibitor coagulant complex)." Nabi, Boca Raton, FL.
Generic Name: anti-inhibitor coagulant complex
Brand Name: Feiba, Feiba VH Immuno, Autoplex T, Feiba NF
Synonyms: Feiba NF (Intravenous), FEIBA NF